Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bristol-Myers signs deal with CytomX

by Ann M. Thayer
March 27, 2017 | A version of this story appeared in Volume 95, Issue 13

Bristol-Myers Squibb and CytomX Therapeutics are expanding a drug discovery collaboration that dates back to 2014. To four ongoing projects the partners will add up to six cancer and two other drug targets using CytomX’s Probody technology. Bristol-Myers will pay $200 million up front, along with research funding and as much as $448 million in potential milestones for each new target. Probody therapeutics are designed to be activated by proteases in the tumor microenvironment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.